Harrow Health, Inc. (HROW)
USD 23.97
(2.11%)
USD 23.97
(2.11%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 116.41 Million USD | 1372.89% |
| 2022 | 7.9 Million USD | -77.92% |
| 2021 | 35.78 Million USD | 84.18% |
| 2020 | 19.43 Million USD | 19.64% |
| 2019 | 16.24 Million USD | 88.64% |
| 2018 | 8.61 Million USD | -23.85% |
| 2017 | 11.3 Million USD | 133.95% |
| 2016 | 4.83 Million USD | -14.81% |
| 2015 | 5.67 Million USD | 169.45% |
| 2014 | -8.16 Million USD | 47.57% |
| 2013 | -15.57 Million USD | -55.24% |
| 2012 | -10.03 Million USD | -881.4% |
| 2011 | 1.28 Million USD | 68.1% |
| 2010 | 764.01 Thousand USD | 148.06% |
| 2009 | -1.58 Million USD | 68.9% |
| 2008 | -5.11 Million USD | -37.9% |
| 2007 | -3.7 Million USD | -9178.91% |
| 2006 | -39.94 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 123.12 Million USD | 5.76% |
| 2024 Q2 | 121.36 Million USD | -1.43% |
| 2023 Q3 | 116.57 Million USD | -20.67% |
| 2023 Q1 | 149.6 Million USD | 1792.74% |
| 2023 FY | 116.41 Million USD | 1372.89% |
| 2023 Q4 | 116.41 Million USD | -0.14% |
| 2023 Q2 | 146.95 Million USD | -1.77% |
| 2022 Q4 | 7.9 Million USD | -77.74% |
| 2022 FY | 7.9 Million USD | -77.92% |
| 2022 Q3 | 35.5 Million USD | 4.6% |
| 2022 Q1 | 37.18 Million USD | 3.89% |
| 2022 Q2 | 33.94 Million USD | -8.72% |
| 2021 Q1 | 14.46 Million USD | -25.55% |
| 2021 FY | 35.78 Million USD | 84.18% |
| 2021 Q2 | 3.81 Million USD | -73.62% |
| 2021 Q3 | 18.83 Million USD | 393.45% |
| 2021 Q4 | 35.78 Million USD | 90.06% |
| 2020 Q1 | 17.1 Million USD | 5.31% |
| 2020 FY | 19.43 Million USD | 19.64% |
| 2020 Q4 | 19.43 Million USD | 3.53% |
| 2020 Q3 | 18.76 Million USD | -7.79% |
| 2020 Q2 | 20.35 Million USD | 19.0% |
| 2019 FY | 16.24 Million USD | 88.64% |
| 2019 Q1 | 16.81 Million USD | 95.32% |
| 2019 Q2 | 16.62 Million USD | -1.15% |
| 2019 Q3 | 16.82 Million USD | 1.19% |
| 2019 Q4 | 16.24 Million USD | -3.44% |
| 2018 Q1 | 12.62 Million USD | 11.67% |
| 2018 Q3 | 8.96 Million USD | -19.47% |
| 2018 Q4 | 8.61 Million USD | -3.96% |
| 2018 FY | 8.61 Million USD | -23.85% |
| 2018 Q2 | 11.13 Million USD | -11.82% |
| 2017 Q2 | 9.24 Million USD | 42.83% |
| 2017 FY | 11.3 Million USD | 133.95% |
| 2017 Q4 | 11.3 Million USD | -1.29% |
| 2017 Q3 | 11.45 Million USD | 23.88% |
| 2017 Q1 | 6.47 Million USD | 33.95% |
| 2016 Q2 | 3.98 Million USD | 247.03% |
| 2016 FY | 4.83 Million USD | -14.81% |
| 2016 Q4 | 4.83 Million USD | -47.7% |
| 2016 Q3 | 9.24 Million USD | 132.19% |
| 2016 Q1 | -2.7 Million USD | -147.72% |
| 2015 Q1 | -2.85 Million USD | 65.0% |
| 2015 Q2 | -1.95 Million USD | 31.62% |
| 2015 Q3 | 1.68 Million USD | 186.39% |
| 2015 Q4 | 5.67 Million USD | 235.88% |
| 2015 FY | 5.67 Million USD | 169.45% |
| 2014 Q2 | -12.08 Million USD | 14.9% |
| 2014 Q3 | -10.31 Million USD | 14.65% |
| 2014 Q4 | -8.16 Million USD | 20.81% |
| 2014 FY | -8.16 Million USD | 47.57% |
| 2014 Q1 | -14.2 Million USD | 8.85% |
| 2013 Q1 | -19.02 Million USD | -89.61% |
| 2013 FY | -15.57 Million USD | -55.24% |
| 2013 Q4 | -15.57 Million USD | 7.42% |
| 2013 Q3 | -16.82 Million USD | 6.36% |
| 2013 Q2 | -17.97 Million USD | 5.56% |
| 2012 Q3 | -10.99 Million USD | -42.42% |
| 2012 Q1 | 462.24 Thousand USD | -64.01% |
| 2012 Q2 | -7.71 Million USD | -1769.51% |
| 2012 Q4 | -10.03 Million USD | 8.69% |
| 2012 FY | -10.03 Million USD | -881.4% |
| 2011 Q3 | 1.1 Million USD | 2.05% |
| 2011 Q2 | 1.08 Million USD | 8.38% |
| 2011 Q1 | 1 Million USD | 31.29% |
| 2011 FY | 1.28 Million USD | 68.1% |
| 2011 Q4 | 1.28 Million USD | 15.76% |
| 2010 FY | 764.01 Thousand USD | 148.06% |
| 2010 Q4 | 764.01 Thousand USD | 263.5% |
| 2010 Q3 | -467.27 Thousand USD | 55.18% |
| 2010 Q2 | -1.04 Million USD | -9.53% |
| 2010 Q1 | -951.88 Thousand USD | 40.12% |
| 2009 Q3 | -1.99 Million USD | 31.12% |
| 2009 FY | -1.58 Million USD | 68.9% |
| 2009 Q2 | -2.9 Million USD | 30.79% |
| 2009 Q4 | -1.58 Million USD | 20.48% |
| 2009 Q1 | -4.19 Million USD | 17.95% |
| 2008 Q4 | -5.11 Million USD | 11.51% |
| 2008 Q2 | -6.71 Million USD | -96.89% |
| 2008 Q3 | -5.77 Million USD | 13.93% |
| 2008 FY | -5.11 Million USD | -37.9% |
| 2008 Q1 | -3.4 Million USD | 8.04% |
| 2007 Q4 | -3.7 Million USD | 13.77% |
| 2007 Q3 | -4.29 Million USD | -25209.69% |
| 2007 Q1 | -27.41 Thousand USD | 0.08% |
| 2007 Q2 | -16.98 Thousand USD | 38.05% |
| 2007 FY | -3.7 Million USD | -9178.91% |
| 2006 Q3 | -28.46 Thousand USD | 0.0% |
| 2006 FY | -39.94 Thousand USD | 0.0% |
| 2006 Q4 | -27.43 Thousand USD | 3.61% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | -6221.088% |
| Alpha Teknova, Inc. | 1.97 Million USD | -5797.518% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | -23.576% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | -55.326% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 73.258% |
| Cosmos Health Inc. | 8.59 Million USD | -1255.143% |
| Journey Medical Corporation | -9.7 Million USD | 1299.063% |
| Embecta Corp. | 1.31 Billion USD | 91.127% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 74.62% |
| Dynavax Technologies Corporation | 106.63 Million USD | -9.173% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 188.984% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 73.098% |
| PainReform Ltd. | -7.95 Million USD | 1564.365% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 844.609% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 844.609% |
| SCYNEXIS, Inc. | -19.35 Million USD | 701.638% |
| Safety Shot Inc | -2.28 Million USD | 5196.23% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 1334.574% |
| Procaps Group, S.A. | 242.93 Million USD | 52.078% |
| Theratechnologies Inc. | 24.87 Million USD | -368.083% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 4719.722% |
| Biofrontera Inc. | 4.05 Million USD | -2770.242% |
| DURECT Corporation | -7.65 Million USD | 1620.996% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 447.234% |
| Cronos Group Inc. | -663.32 Million USD | 117.55% |
| OptiNose, Inc. | 58.06 Million USD | -100.494% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 81.325% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 898.909% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 2344.819% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -675.441% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 1930.558% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -108844.497% |
| Radius Health, Inc. | 359.28 Million USD | 67.597% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -58932.296% |
| ProPhase Labs, Inc. | 19.23 Million USD | -505.361% |
| Phibro Animal Health Corporation | 454.84 Million USD | 74.405% |
| Procaps Group S.A. | 242.93 Million USD | 52.078% |
| Alvotech | 1.06 Billion USD | 89.062% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -3065.226% |
| Viatris Inc. | 17.13 Billion USD | 99.32% |
| Rockwell Medical, Inc. | 4.45 Million USD | -2512.59% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 2487.062% |
| SIGA Technologies, Inc. | -148.68 Million USD | 178.299% |
| Tilray Brands, Inc. | 158.97 Million USD | 26.771% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 4.496% |
| Shineco, Inc. | 29.29 Million USD | -297.459% |
| PetIQ, Inc. | 351.93 Million USD | 66.921% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 4112.404% |
| Incannex Healthcare Limited | -5.48 Million USD | 2222.461% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 34.339% |
| Alimera Sciences, Inc. | 55.3 Million USD | -110.485% |
| Silver Spike Investment Corp. | -32.61 Million USD | 456.98% |
| Assertio Holdings, Inc. | -32.52 Million USD | 457.887% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 7919.929% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 2400.557% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 2518.301% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 1517.39% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -2660.659% |
| Hempacco Co., Inc. | 13.61 Million USD | -755.084% |
| Talphera, Inc. | -5.72 Million USD | 2134.906% |
| Alvotech | 1.06 Billion USD | 89.062% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | -1529.349% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 220.377% |
| Currenc Group, Inc. | -16.57 Million USD | 802.444% |
| Kamada Ltd. | -46.43 Million USD | 350.728% |
| Indivior PLC | -33.95 Million USD | 442.887% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -44577.136% |
| Flora Growth Corp. | -713 Thousand USD | 16427.77% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 1517.39% |
| Evolus, Inc. | 63.7 Million USD | -82.735% |
| HUTCHMED (China) Limited | -197.45 Million USD | 158.958% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 75.701% |
| Akanda Corp. | 3.9 Million USD | -2881.293% |